Asset profile
Buparlisib
Small molecule
Evidence outlook
Phase 2 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT01852292) was terminated, and no study is currently active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
5 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 5 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Buparlisib: this drug | Phase 3 | Small molecule | PI3K inhibitor (pan-class I) | ||
| Monalizumab | Phase 3 | Monoclonal antibody | NKG2A | ||
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | ||
| INBRX-106 | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | ||
| CAB-ROR2-ADC | Phase 1/2 | Monoclonal antibody | ROR2 | ||
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.